best casino bonuses australian online casino au dollars trusted online gambling internet casino download old information online us casinos las vegas best online casino craps flash casino games mac play online vegas

Get Our Newsletter


[quads id=4]

Links

Columnists



Site Search


Entire (RSS)
Comments (RSS)

Archive Calendar

May 2018
S M T W T F S
« Apr    
 12345
6789101112
13141516171819
20212223242526
2728293031  

Guides

How to Become a Bounty Hunter


[quads id=3]

Opinion Piece: DEA Has No Clue What It’s Talking About When it Comes to Pot and Opioids

Paul Armentano is the deputy director of the National Organization for the Reform of Marijuana Laws. He is the co-author of the book, Marijuana Is Safer: So Why Are We Driving People to Drink? and the author of the book, The Citizen’s Guide to State-By-State Marijuana Laws. This piece appears in The Hill.

By Paul Armentano
For The Hill

Is state-level medical cannabis access mitigating or fueling America’s opioid crisis? Testifying before Congress last week, Drug Enforcement Agency (DEA) acting administrator Robert Patterson claimed the latter. But when he prompted to provide evidence in support of the agency’s position, he acknowledged that he could not.

His failure to substantiate this claim is unsurprising. That is because numerous peer-reviewed studies show that increased cannabis access is associated with declining rates of opioid useabusehospitalizations, and mortality. Among patients enrolled in state-sanctioned medical marijuana access programs, participants’ use of not only opioids, but also their use of numerous other prescription medications — such as anti-depressants and anti-anxiety drugs — declines significantly.

To read the full piece click here.

Print This Post Print This Post

Write a comment

You need to login to post comments!

[quads id=1]